Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Health Utilities Using the EQ-5D in Studies of Cancer
- A. S. Pickard, C. Wilke, Hsiang-Wen Lin, A. Lloyd
- Medicine
- PharmacoEconomics
- 2012
Cancer is one of the most frequent disease-specific applications of the EQ-5D. The objective of this review was to summarise evidence to support the validity and reliability of the EQ-5D in cancer,… Expand
Use of a preference-based measure of health (EQ-5D) in COPD and asthma.
- A. S. Pickard, C. Wilke, Eunmi Jung, S. Patel, K. Stavem, T. Lee
- Medicine
- Respiratory medicine
- 1 April 2008
BACKGROUND
EQ-5D is a generic preference-based measure of health that can help to understand the impact of asthma and chronic obstructive pulmonary disease (COPD). The purpose of this paper was to… Expand
Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease.
- T. Lee, C. Wilke, +4 authors A. S. Pickard
- Medicine
- Archives of internal medicine
- 10 August 2009
BACKGROUND
To date, there is mixed evidence on the safety and effectiveness of tiotropium. Our objective was to evaluate the comparative effectiveness of regimens containing tiotropium bromide vs… Expand
Disease-specific patient reported outcome tools for systemic lupus erythematosus.
- M. Jolly, A. S. Pickard, +16 authors D. Wallace
- Medicine
- Seminars in arthritis and rheumatism
- 1 August 2012
PURPOSE
Systemic lupus erythematosus (SLE) can significantly affect both health and non-health-related quality of life (HRQOL and non-HRQOL). However, of the existent published patient-reported… Expand
Statistical implications of utility weighted and equally weighted HRQL measures: an empirical study.
- C. Wilke, A. S. Pickard, S. M. Walton, J. Moock, T. Kohlmann, T. Lee
- Mathematics, Medicine
- Health economics
- 26 February 2009
The utility-based approach to health measurement, exemplified by EQ-5D and Health Utilities Index (HUI), has been challenged on a theoretical basis, but the statistical implications of such an… Expand
Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via…
- R. Ballal, M. Botteman, I. Foley, J. Stephens, C. Wilke, A. V. Joshi
- Medicine
- Current medical research and opinion
- 29 January 2008
ABSTRACT Objectives: People with severe hemophilia suffer from frequent intra-articular hemorrhages, leading to pain, swelling, reduced flexion, and arthropathy. Elective orthopedic surgery using… Expand
Exposure and safety of higher doses of recombinant factor VIIa ≥250 μg kg−1 in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research…
- E. Neufeld, C. Kessler, J. Gill, C. Wilke, D. Cooper
- Medicine
- Haemophilia : the official journal of the World…
- 1 July 2011
Summary. Recombinant factor VIIa (rFVIIa) is a well‐established treatment for managing bleeding episodes in individuals with congenital haemophilia complicated by alloantibody inhibitors (CHwI). The… Expand